Intellia Therapeutics initiated with a Buy at BTIG. BTIG analyst Amanda Murphy initiated Intellia Therapeutics with a Buy rating and $20 price target. Murphy said Intellia’s in vivo pipeline is the “most well-characterized” of the public gene editing companies, and she sees upside from wholly-owned programs in oncology and CNS.
https://thefly.com/landingPageNews.php?id=2861463
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.